H3n2 influenza virus treatment

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. H3 mRNA/LNP Vaccine overview The vaccine candidate is under development for the prevention of disease caused by H3N2 influenza virus infections in adults aged 18 to 49 Years and 60 Years and above. It comprises of monovalent modified mRNA encoding the full-length hemagglutinin (HA) sequence of A/Tasmania/503/2020 (H3N2) influenza virus encapsulated in lipid nanoparticle (LNP). The vaccine is administered intramuscularly as a suspension. Sanofi overview For a complete picture of H3 mRNA/LNP Vaccine’s drug-specific PTSR and LoA scores,